Another Weapon for Fighting Fear
PTSD exposure therapy treatment enhanced by d cycloserine drug
Reviewed By: Joseph V. Madia, MD
By: Tara Haelle
Published: Jun 8, 2012
(dailyRx)
While exposure therapy remains the first line of defense for post-traumatic stress disorder, it remains an imperfect treatment. But an inexpensive drug may enhance its effectiveness.
A recent study has found some evidence that patients experiencing especially severe PTSD may respond better to psychotherapy if they supplement it with the drug D-cycloserine.
Dr. Rianne de Kleine, of the Radboud University Nijmegen Behavioral Science Institute and Center for Anxiety Disorders Overwaal in the Netherlands, led the study to see if it was possible to improve exposure therapy outcomes for patients suffering from PTSD.
Exposure therapy involves repeatedly exposing a person to thinking about, discussing or even experiencing the traumatic events that caused their PTSD in a safe place.
The goal is for people to begin associating those traumatic experiences with a safer environment as they get used to living with their memories and for the memories to lose their power over the person.
The treatment works, but it doesn't work for everyone. Many people drop out of psychotherapy, and others' symptoms persist. read more here
Sunday, June 10, 2012
Another Weapon for Fighting Fear, again?
This is based on a small study but it could be useful for someone out there. As the article points out, "treatment does not work for everyone" and you should keep trying until you find what works best for you. Medications are different person to person because what works for your buddy may not work for you. Treatment is different as well. Some do great in group sessions while others need one-on-one. It all depends on you. Keep looking for "your space" in all of this and talk to your doctor if what you're getting is not helping.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
If it is not helpful, do not be hurtful. Spam removed so do not try putting up free ad.